Price$2.13+0.00 (+0.00%)
2025-07-172025-10-17
News · 26 weeks4-100%
2025-12-072026-05-31
Mix390d
- SEC Filings3(100%)
Latest news
25 items- SECSEC Form PRE 14A filed by Orgenesis Inc.PRE 14A - Orgenesis Inc. (0001460602) (Filer)
- SECSEC Form 10-K filed by Orgenesis Inc.10-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Leadership Update8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- SECSEC Form NT 10-Q filed by Orgenesis Inc.NT 10-Q - Orgenesis Inc. (0001460602) (Filer)
- SECSEC Form 25-NSE filed by Orgenesis Inc.25-NSE - Orgenesis Inc. (0001460602) (Subject)
- SECOrgenesis Inc. filed SEC Form 8-K: Other Events8-K - Orgenesis Inc. (0001460602) (Filer)
- SECSEC Form NT 10-K filed by Orgenesis Inc.NT 10-K - Orgenesis Inc. (0001460602) (Filer)
- INSIDERNew insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)3 - Orgenesis Inc. (0001460602) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Orgenesis Inc.SCHEDULE 13G - Orgenesis Inc. (0001460602) (Subject)
- NEWSOrgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury TherapiesStrategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced the acquisition of certain Neurocords LLC's ("Neurocords") assets related to advanced regenerative medicine therapies for spinal cord injuries (SCI). The global spinal cord injury treatment market size was valued at $7.5 billion in 2023 and is projected to reach $11.2 billion by 2031 according to Data Bridge Mark
- SECOrgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Orgenesis Inc. (0001460602) (Filer)
- NEWSOrgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsFunding Aimed at Accelerating Rollout of Decentralized CGT Platform GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that it has concluded an agreement for an equity line of credit of up to $5 million from Williamsburg Venture Holdings, LLC, a Nevada-based family office.Under the terms of the agreement, Orgenesis will receive $750,000 upon the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission. According to the te
- SECSEC Form 8-K filed by Orgenesis Inc.8-K - Orgenesis Inc. (0001460602) (Filer)
- SECOrgenesis Inc. filed SEC Form 8-K: Leadership Update8-K - Orgenesis Inc. (0001460602) (Filer)
- INSIDERSEC Form 4 filed by Director Vider Itzhak4 - Orgenesis Inc. (0001460602) (Issuer)
- INSIDERSEC Form 4 filed by Director Adler Yaron4 - Orgenesis Inc. (0001460602) (Issuer)
- INSIDERSEC Form 4 filed by Director Pelavin Adam4 - Orgenesis Inc. (0001460602) (Issuer)
- INSIDERSEC Form 4 filed by Director Nagaraj Santhosh4 - Orgenesis Inc. (0001460602) (Issuer)
- INSIDERSEC Form 4 filed by Director Nanda Ashish4 - Orgenesis Inc. (0001460602) (Issuer)
ORGS FAQ
5 questionsWhat does Orgenesis Inc. do?
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient...Where does ORGS stock trade?
Orgenesis Inc. (ORGS) is listed on NASDAQ.What sector and industry is ORGS in?
Orgenesis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to ORGS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ORGS side-by-side with any of them on Quantisnow.How can I track ORGS on Quantisnow?
Quantisnow aggregates Orgenesis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORGS to receive live email and push alerts on every new disclosure.